Perhaps the most compelling data regarding the synergy of APR-246 and azacitidine originates from the clinical activity in TP53 mutant MDS/AML patients, where recent data report an overall and complete remission rate of 87% and 53%, respectively ( clinicaltrials.gov identifier: NCT03072043 ).9 Similarly, preliminary results from a phase II study of APR-246 and azacitidine by the Groupe Francophone des Mylodysplasies ( clinicaltrials.gov identifier: NCT03588078 ) showed comparable response rates.10 Accordingly, the US Food and Drug Administration has recently granted breakthrough therapy designation for the treatment of patients with TP53 mutant MDS with the combination of APR-246 and azacitidine and the randomized phase III study of APR-246 and azacitidine versus azacitidine is ongoing in MDS patients ( clinicaltrials.gov identifier: NCT03745716 )
Lets understand key areas like mechanism of action, therapeutic use, administration, potential side effects, and clinical trial outcomes
It is too hot to walk at noon, schedules shift around travel, and the Strip is full of easy detours from a plan
Tardiff, D
Nazarians trusted methodology an integrative plan that includes microdosing , smart supplementation, and tailored nutrition
Quick and thorough Watersafe is a fast and reliable way to check for dangerous levels of]]bacterial contaminants in your water
-1.jpg)
